Elranatamab and Mezigdomide Combination Therapy

A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
62
Last Updated

Participating Centers

There are 4 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Elranatamab
  • Mezigdomide
  • Dexamethasone

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Phase 1

Not yet accepting

Phase 2

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print this trial to share with your doctor.

(888) 828-2206

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.